By Fineline Cube 
Astellas Pharma (TYO: 4503) announced on October 27, 2025, the establishment of its first China Innovation R&D Center in Beijing. The center will be located in the Beijing International Pharmaceutical Innovation Park (BioPark) within the Beijing Economic-Technological Development Area. This initiative complements Astellas’ existing innovation hubs in Tokyo, San Francisco, Boston, Chicago, and Cambridge (UK), marking the company’s first innovation R&D center in China since entering the market 31 years ago.
Strategic Significance
China has emerged as a global hub for pharmaceutical innovation and is among Astellas Group’s most critical markets worldwide. Astellas plans to leverage the BioPark’s innovation ecosystem and policy advantages to address the unmet clinical needs of Chinese patients and accelerate the development and delivery of breakthrough therapies.-Fineline Info & Tech